Skip to main content

Drug Interactions between Cubicin RF and Trilipix

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

DAPTOmycin fenofibric acid

Applies to: Cubicin RF (daptomycin) and Trilipix (fenofibric acid)

GENERALLY AVOID: There is some theoretical concern regarding the potential for additive musculoskeletal toxicity during coadministration of daptomycin and other drugs associated with myopathy, such as fibric acid derivatives. In animals, daptomycin has been associated with skeletal muscle effects characterized by degenerative/regenerative changes and variable elevations in creatine phosphokinase (CPK). Elevations in serum CPK were also reported more frequently in daptomycin-treated patients than in comparator-treated patients (2.8% vs. 1.8%) in phase 3 clinical trials. Similarly, fibrates are known to occasionally cause myopathy manifested as muscle pain and/or weakness in association with grossly elevated levels of CPK. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria. Myopathy has not been reported in clinical trials of daptomycin.

MANAGEMENT: Due to the limited nature of existing data, consideration should be given to temporarily suspending use of fibrates in patients receiving daptomycin. All patients receiving daptomycin should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. CPK levels should be monitored weekly, and patients who develop unexplained elevations in CPK should be monitored more frequently. Daptomycin should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK levels exceeding 1000 U/L (approximately 5 times the upper limit of normal), or in patients without reported symptoms who have marked elevations in CPK (10 times the upper limit of normal, or more).

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer